On October 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) announced that it has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., securing worldwide rights to TELI’s lead investigational therapy, Telomir‑1. The agreement, signed in Miami, Florida, is expected to unlock up to $5 million in potential shareholder contributions and establishes a comprehensive global intellectual‑property framework for the compound.
The transaction expands Telomir’s IP portfolio and provides a foundation for future partnerships and licensing agreements. By obtaining worldwide rights to Telomir‑1, the company positions itself to pursue commercial opportunities across all regions, potentially accelerating the path to clinical development and market entry.
Telomir’s focus on epigenetic drivers of cancer, aging, and age‑related disease makes the acquisition strategically aligned with its preclinical pipeline. Securing global rights to a promising lead candidate enhances the company’s competitive moat and may increase its attractiveness to investors and collaborators.
The LOI signals a significant step toward commercial viability, offering a platform for future licensing deals, joint ventures, and potential revenue streams as Telomir advances Telomir‑1 toward IND submission and human trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.